Clinical Trial Detail

NCT ID NCT02512172
Title A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

colorectal cancer

Therapies

Azacitidine + Pembrolizumab

Pembrolizumab + Romidepsin

Azacitidine + Pembrolizumab + Romidepsin

Age Groups: senior adult

No variant requirements are available.